Cas:1066-38-2 iodo(trimethyl)germane manufacturer & supplier

We serve Chemical Name:iodo(trimethyl)germane CAS:1066-38-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

iodo(trimethyl)germane

Chemical Name:iodo(trimethyl)germane
CAS.NO:1066-38-2
Synonyms:trimethylgermanium iodide;Iodotrimethylgermane;trimethylgermyl iodide;Iod-trimethyl-german;MFCD00013700;Trimethylgermaniumiodid
Molecular Formula:C3H9GeI
Molecular Weight:244.64800
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:134ºC(lit.)
Density:1.815 g/mL at 25ºC(lit.)
Index of Refraction:1.5189
PSA:
Exact Mass:245.89600
LogP:2.25630

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3265 8/PG 2
Packing Group:


Contact us for information like trimethylgermanium iodide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Trimethylgermaniumiodid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,trimethylgermyl iodide Use and application,Trimethylgermaniumiodid technical grade,usp/ep/jp grade.


Related News: The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries. iodo(trimethyl)germane manufacturer As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. iodo(trimethyl)germane supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). iodo(trimethyl)germane vendor The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data. iodo(trimethyl)germane factory The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries.